TY  - BOOK
AU  - Shara, Nawar M
TI  - Chronic leg ulceration associated with polycythemia vera responding to ruxolitinib (Jakafi())
SN  - 1067-2516
PY  - 2013///
KW  - *Enzyme Inhibitors/tu [Therapeutic Use]
KW  - *Janus Kinases/ai [Antagonists & Inhibitors]
KW  - *Polycythemia Vera/co [Complications]
KW  - *Pyrazoles/tu [Therapeutic Use]
KW  - *Skin Ulcer/dt [Drug Therapy]
KW  - *Wound Healing/de [Drug Effects]
KW  - Antimetabolites/ae [Adverse Effects]
KW  - Chronic Disease
KW  - Enzyme Inhibitors/pd [Pharmacology]
KW  - Humans
KW  - Hydroxyurea/ae [Adverse Effects]
KW  - Leg
KW  - Male
KW  - Middle Aged
KW  - Pyrazoles/pd [Pharmacology]
KW  - Skin Transplantation
KW  - Skin Ulcer/su [Surgery]
KW  - Wounds and Injuries/dt [Drug Therapy]
KW  - Wounds and Injuries/su [Surgery]
KW  - MedStar Health Research Institute
KW  - Case Reports
KW  - Journal Article
KW  - Research Support, N.I.H., Extramural
N1  - Available online through MWHC library: 2003 - present, Available in print through MWHC library:1999-2007
N2  - We present the case of a 63-year-old white male with bilateral chronic leg ulcers due to polycythemia vera and hydroxyurea therapy who demonstrated dramatic healing of his wounds in response to ruxolitinib (Jakafi(), Novartis), a novel Janus kinase-1 and -2 inhibitor. This patient's wound had previously been refractory to multiple surgical interventions and immunosuppression. After the initiation of ruxolitinib, the patient underwent successful split-thickness skin grafting, with resultant healing of his wounds. He was stable without prednisone and other immunosuppressant therapy and had healed at 6 months. Ruxolitinib therapy could represent a novel option for patients who develop persistent inflammatory wounds in the setting of polycythemia vera and hydroxyurea therapy. Copyright  2013 American College of Foot and Ankle Surgeons. Published by Elsevier Inc. All rights reserved
UR  - http://dx.doi.org/10.1053/j.jfas.2013.07.003
ER  -